Loading

logo

Journal of AIDS and HIV Treatment

ISSN: 2688-7436

Research Article Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/AIDS.4.026

Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)

Matthew A. Thimm1, Alison Livingston1, Rosemary Ramroop1, Ahizechukwu C. Eke2,*
  • 1Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
  • 2Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA
+ Affiliations - Affiliations

Corresponding Author

Ahizechukwu C Eke, aeke2@jhu.edu

Received Date: February 02, 2022

Accepted Date: March 07, 2022

Citation:

Thimm MA, Livingston A, Ramroop R, Eke AC. Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) compared to Tenofovir Alafenamide (TAF). J AIDS HIV Treat. 2022;4(1):6-13.


Copyright: © 2022 Thimm MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Objective: Our objective was to assess the safety, efficacy, and pregnancy outcomes of Tenofovir Disoproxil Fumarate (TDF) compared to Tenofovir Alafenamide (TAF) use in pregnant women with HIV (PWLHIV).

Methods: This retrospective cohort study of all women who received prenatal care at a single academic center between January 1st 2015 and June 30th, 2020 compared outcomes in PWLHIV using TDF compared to TAF. The primary outcome was weight-gain during pregnancy. Secondary outcomes included CD4 count, viral-load, gestational age at delivery, fetal and neonatal outcomes. Outcomes were analyzed using standard statistical tests. Multivariable linear-regression analysis models accounting for potential confounders were created for primary and secondary outcomes, with beta coefficients (β) and associated 95% confidence intervals as the primary measure of effect. Statistical analysis was done with STATA 16.

Results: There were 66 women in the TDF group and 34 women in the TAF group. In the overall cohort, the median (interquartile range, IQR) gestational age at delivery for PWLHIV on TDF and TAF were 38.6 (IQR 37.5-39.4) and 38.1 (31.1-39.1) weeks respectively; and most women (85%) were Black/African American. Compared to PWLHIV on a TDF regimen, women on TAF, on average, gained over 3 kg more weight in the 3rd trimester of pregnancy (β=3.20, 95% CI 1.64, 7.97; p=0.03). Women in the TAF arm were also more likely to have higher median CD4-count (470 cells/mm3 versus 669 cells/mm3, p=0.035) in the third trimester compared to women on TDF. There were no cases of neonatal/infant HIV or death.

Conclusion: Although TAF use was associated with more weight gain compared to TDF, both regimens appear safe and effective during pregnancy. PWLHIV should be counseled about the potential for weight gain with TAF based regimens during pregnancy.

Keywords

Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, Antiretroviral agents, HIV, AIDS, Pregnancy, Weight gain

Recommended Articles

Low-level Progesterone on the Day of hCG Injection Has No Detrimental Effect on the Pregnancy Outcome after IVF with GnRH-a Protocol: A Retrospective Study

To investigate the effect of low progesterone (P) level on the day of human chorionic gonadotropin (hCG) injection on the outcome of in vitro fertilization (IVF) with GnRH- agonist (GnRH-a) long protocol.

Evaluation and Management of chronic Hypertension in Pregnancy

Chronic hypertension is present in 1-2% of pregnant women. Women with chronic hypertension are at an increased risk of maternal and perinatal complications when compared with normotensive women.

Critical Appraisal OF Cervical Pregnancy Management

For a long time, it was rare to see a case of cervical pregnancy (CP) throughout the journey in the field of obstetrics. Recently, the circumstances showed dramatic changes and I think not uncommonly every one elsewhere in the field may face this problem to some extent and the CP term strikes his/her ears.

Tenofovir at the Crossroad of the Therapy and Prophylaxis of HIV and HBV Infections

Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 [1]. That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.

Adnexal Torsion During the Second Trimester of Pregnancy: Mc Burney Incision and Management Strategy

A 33-year-old pregnant woman at 26 weeks gestation presented with abdominal pain in the right iliac fossa. She had a history of a left ovarian cyst. The current pregnancy was normal. The patient was apyretic.

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More